Premium
Move to eliminate x‐waiver gathers steam, aimed at federal legislation
Author(s) -
Knopf Alison
Publication year - 2021
Publication title -
alcoholism and drug abuse weekly
Language(s) - English
Resource type - Journals
eISSN - 1556-7591
pISSN - 1042-1394
DOI - 10.1002/adaw.32956
Subject(s) - waiver , administration (probate law) , legislation , buprenorphine , political science , public administration , addiction , medicine , law , psychiatry , receptor , opioid
The ripples toward deregulating buprenorphine became a tsunami last week. This time, it's aiming straight for Congress, as the Trump administration's clumsy attempt to steer it through the last days of the previous administration failed. Among the new voices added to the debate: patient advocacy group NAMA Recovery, and the American Association for Addiction Medicine (ASAM).